Prostate Cancer

Title Average Ratingsort ascending
75 year old man, Prostate Cancer with bone and liver metastasis 100.00%
Intermittent androgen deprivation therapy: redefining the standard of care? 100.00%
Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate c 100.00%
Bio-Immune therapy according to Professor Thomas Tallberg, a cure for Melanoma? 98.00%
An Integrated Cancer Treatment program. 97.50%
Phase II study of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) ...... 95.00%
Todoxin, the immune stimulant from Serbia 92.50%
A 4-week home-based aerobic and resistance exercise program during radiation therapy: a pilot randomized clinical trial. 90.00%
Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prosta 90.00%
A randomized trial of personalized peptide vaccine (PPV) plus low-dose estramustine (EMP) versus full-dose EMP in patients ..... 90.00%
Randomized Trials of Selenium, Vitamin E, or Vitamin C for Prostate Cancer Prevention 90.00%
20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and 90.00%
Update on pilot study on antitumor efficacy of intravenously applied synergistic combinations of diflunisal, PAS, and aspirin in patients with advanced solid tumors. 90.00%
NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell 90.00%
Clinical Investigations on Ukrain 90.00%
GcMAF-The cancer revolution from Japan 87.33%
Systems biology: a therapeutic target for tumor therapy. 86.67%
82 year old man with prostate cancer 85.00%
Dramatic prostate-specific antigen response with activated hemicellulose compound in metastatic castration-resistant prostate ca 80.00%
Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. 80.00%
High-dose medroxyprogesterone acetate versus estramustine in therapy-resistant prostatic cancer: a randomised study. 80.00%
Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. 80.00%
Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer. 80.00%
Sanguinarine suppresses prostate tumor growth and inhibits survivin expression. 80.00%
Clinical experience of integrative cancer immunotherapy with GcMAF. 80.00%
Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen 80.00%
Melatonin as biological response modifier in cancer patients. 80.00%
Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. 80.00%
Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refract 80.00%
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. 80.00%
Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer 80.00%
Cytochrome P-450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect. 80.00%
An orally active Amazonian plant extract (BIRM) inhibits prostate cancer growth and metastasis. 80.00%
Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. 80.00%
Metformin in the treatment of Cancer 77.00%
Removed from Pubmed because of suspiion of scientific fraud: Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF. 75.00%
Cancer Psychotherapy according to Dr. Frederick B Levenson 73.33%
Focal laser ablation of prostate cancer: definition, needs, and future 70.00%
Association between serum 25(OH)D and death from prostate cancer. 70.00%
Oncolytic virus therapy for prostate cancer. 70.00%
Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. 70.00%
Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. 70.00%
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-indep.. 70.00%
A phase II trial of an adenovirus/PSA vaccine for prostate cancer. 70.00%
Milk consumption is a risk factor for prostate cancer in Western countries: evidence from cohort studies. 70.00%
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline 70.00%
Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. 60.00%
A phase II clinical trial of sorafenib in androgen-independent prostate cancer. 60.00%
Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of 60.00%
Focal therapy for prostate cancer: revolution or evolution? 60.00%
Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. 60.00%
Serum calcium and the risk of prostate cancer. 60.00%
Update on pilot study on antitumor efficacy of intravenously applied synergistic combinations of diflunisal, PAS, and aspirin in patients with advanced solid tumors. 60.00%
Review. Current role and future perspectives of hyperthermia for prostate cancer treatment. 60.00%
Vitamin D and prostate cancer risk: a review of the epidemiological literature. 60.00%
Gallic acid, a major component of Toona sinensis leaf extracts, contains a ROS-mediated anti-cancer activity in human prostate 60.00%
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. 50.00%
Results of Ukrain monotherapy of prostate cancer 50.00%
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. 50.00%
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. 50.00%
Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryother 50.00%
Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. 50.00%
Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities 50.00%
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer. 50.00%
Induced apoptosis in human prostate cancer cell line LNCaP by Ukrain. 0.00%
Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) stud 0.00%
Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age. 0.00%